Manifesto on inhaled triple therapy in asthma: an Interasma (Global Asthma Association – GAA) document

The optimal use of drug combinations for the management of asthma is providing significant results. This has prompted INTERASMA (Global Asthma Association) to take a position on inhaled triple therapy in asthma. Starting from an extensive literature review, Interasma executive committee discussed and approved this Manifesto, developed by Interasma scientific network (INES) members. The manifesto describes the evidence gathered to date and states, advocates, and proposes issues on Inhaled corticosteroid (ICS) plus Long-acting beta 2 agonist (LABA) and long-acting muscarinic antagonists (LAMA) with the aim of challenging assumptions, fostering commitment, and bringing about change.

[1]  H. Sagara,et al.  Efficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study , 2021, Current medical research and opinion.

[2]  P. O'Byrne,et al.  Triple vs Dual Inhaler Therapy and Asthma Outcomes in Moderate to Severe Asthma: A Systematic Review and Meta-analysis. , 2021, JAMA.

[3]  “Real-life” management of patients with severe asthma in the biologics era: Can we do better?☆ , 2021, The World Allergy Organization journal.

[4]  H. Sagara,et al.  Efficacy of one time per day, single-inhaler indacaterol/glycopyrronium/mometasone in patients with inadequately controlled asthma: post hoc analysis of IRIDIUM study in Asian population , 2021, BMJ Open Respiratory Research.

[5]  Shuying Yang,et al.  Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN) , 2021, Clinical Pharmacokinetics.

[6]  H. Kerstjens,et al.  Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials. , 2021, Respiratory medicine.

[7]  L. Boulet,et al.  Manifesto on united airways diseases (UAD): an Interasma (global asthma association – GAA) document , 2021, The Journal of asthma : official journal of the Association for the Care of Asthma.

[8]  J. Virchow,et al.  Extrafine triple therapy and asthma exacerbation seasonality: TRIMARAN and TRIGGER post-hoc analyses. , 2021, The Journal of allergy and clinical immunology.

[9]  F. Cardoso,et al.  Why is appropriate healthcare inaccessible for many European breast cancer patients? – The EBCC 12 manifesto , 2021, Breast.

[10]  H. Watz,et al.  Lung function improvements following inhaled indacaterol/glycopyrronium/mometasone furoate are independent of dosing time in asthma patients: a randomised trial , 2020, ERJ Open Research.

[11]  Ju-Young Shin,et al.  Cost-effectiveness of tiotropium in elderly patients with severe asthma using real-world data. , 2020, The journal of allergy and clinical immunology. In practice.

[12]  J. Virchow,et al.  Determinants of response to inhaled extrafine triple therapy in asthma: analyses of TRIMARAN and TRIGGER , 2020, Respiratory Research.

[13]  A. Lala,et al.  A manifesto of collaborative longitudinal cardiovascular care in heart failure , 2020, Heart Failure Reviews.

[14]  C. Gessner,et al.  Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON). , 2020, Respiratory medicine.

[15]  J. Virchow,et al.  Extrafine triple therapy in patients with asthma and persistent airflow limitation , 2020, European Respiratory Journal.

[16]  J. Fairburn-Beech,et al.  Clinical characteristics, treatment patterns, disease burden, and persistence/adherence in patients with asthma initiating inhaled triple therapy: real-world evidence from Japan , 2020, Current medical research and opinion.

[17]  E. Bleecker,et al.  Tiotropium Respimat efficacy and safety in asthma: Relationship to age. , 2020, The journal of allergy and clinical immunology. In practice.

[18]  H. Watz,et al.  Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study , 2020, Respiratory Research.

[19]  E. Bleecker,et al.  Efficacy of once-daily tiotropium Respimat in adults with asthma at GINA Steps 2-5. , 2019, Pulmonary pharmacology & therapeutics.

[20]  M. Orrell,et al.  Bridging the divide between biomedical and psychosocial approaches in dementia research: the 2019 INTERDEM manifesto , 2019, Aging & mental health.

[21]  T. Casale,et al.  Tiotropium reduces airflow obstruction in asthma patients, independent of body mass index. , 2019, The journal of allergy and clinical immunology. In practice.

[22]  Kenta Akitsu,et al.  Comparison between montelukast and tiotropium as add-on therapy to inhaled corticosteroids plus a long-acting β2-agonist in for patients with asthma , 2018, The Journal of asthma : official journal of the Association for the Care of Asthma.

[23]  C. White,et al.  Association of Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists With Asthma Control in Patients With Uncontrolled, Persistent Asthma: A Systematic Review and Meta-analysis , 2018, JAMA.

[24]  J. Virchow,et al.  Tiotropium Respimat Add-on Is Efficacious in Symptomatic Asthma, Independent of T2 Phenotype. , 2017, The journal of allergy and clinical immunology. In practice.

[25]  A. Abernethy,et al.  Repurposing Medications for Hospice/Palliative Care Symptom Control Is No Longer Sufficient: A Manifesto for Change. , 2017, Journal of pain and symptom management.

[26]  T. Iwanaga,et al.  Effects of tiotropium on lung function in current smokers and never smokers with bronchial asthma. , 2017, Pulmonary pharmacology & therapeutics.

[27]  Kenta Akitsu,et al.  Effects of the addition of tiotropium on airway dimensions in symptomatic asthma. , 2016, Allergy and asthma proceedings.

[28]  E. Bateman,et al.  Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status. , 2016, Respiratory medicine.

[29]  K. Ohta,et al.  Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study , 2015, PloS one.

[30]  E. Pizzichini,et al.  Once-daily tiotropium Respimat(®) 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma. , 2015, Respiratory medicine.

[31]  Y. Nakanishi,et al.  Effects of tiotropium on lung function in severe asthmatics with or without emphysematous changes. , 2013, Pulmonary pharmacology & therapeutics.

[32]  H. Kerstjens,et al.  Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. , 2011, The Journal of allergy and clinical immunology.

[33]  H. Magnussen,et al.  Improvements with tiotropium in COPD patients with concomitant asthma. , 2008, Respiratory medicine.